MAF1 protein expression is significantly decreased in luminal, HER2-positive, and TNBC breast cancer subtypes and MAF1 mRNA expression is increased substantially in breast cancer cell lines treated with anti-HER2 therapies. Here, MAF1 is linked to breast cancer.